Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically diagnosed:

- Acute myeloid leukemia in first, second, or third complete remission or first or
second early relapse

- Acute lymphoblastic leukemia in first, second, or third complete remission or
first or second early relapse

- Hodgkin's lymphoma in second or third remission or first, second, or third
relapse, or refractory

- Non-Hodgkin's lymphoma in second or third remission or first, second, or third
relapse, or refractory

- Multiple myeloma and plasma cell leukemia in second or third remission or first,
second, or third relapse, or refractory

- Myelodysplastic syndrome deemed suitable for allogeneic bone marrow
transplantation

- No symptoms or signs of CNS involvement and CNS is disease free on lumbar puncture
and brain CT scan

- No active meningeal cancer

PATIENT CHARACTERISTICS:

Age:

- 4 to 55 (4 to 60 if donor is identical twin)

Performance status:

- ECOG 0-2

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- SGOT/SGPT less than 3 times normal

- Bilirubin less than 2.0 mg/dL

Renal:

- Creatinine less than 2.1 mg/dL

- Creatinine clearance at least 60 mL/min (no greater than 1.5 times normal for
children under 40 kg)

Cardiovascular:

- No uncontrolled hypertension

- No uncontrolled congestive heart failure

- No active angina pectoris requiring nitrates

- At least 6 months since prior myocardial infarction

- No major ventricular arrhythmia

- Left ventricular ejection fraction at least 45% on MUGA

Pulmonary:

- No severe or symptomatic restrictive or obstructive lung disease

- FEV_1 greater than 50% of predicted

- DLCO greater than 50% of predicted

Neurologic:

- No severe central or peripheral neurologic abnormality

Other:

- Must have HLA-A,B,C,D/DR identical sibling age 4 to 65, in good health

- No insulin-dependent diabetes mellitus

- No major thyroid or major adrenal dysfunction

- No active infection

- No other active malignancy

- Not pregnant

- HIV negative

- HTLV-I and HTLV-II negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No excessive anthracycline exposure, unless endomyocardial biopsy shows less than
grade 2 drug effect and cardiac scan shows at least 50% ejection fraction

- At least 1 year since prior autologous bone marrow or peripheral blood progenitor
cell transplant or allogeneic bone marrow transplant

Chemotherapy:

- At least 3 weeks since prior chemotherapy

- No prior excessive carmustine and bleomycin

Endocrine therapy:

- Not specified

Radiotherapy:

- At least 3 weeks since prior radiotherapy

Surgery:

- Not specified

Other:

- No concurrent nitroglycerin for angina pectoris

- No concurrent anti-arrhythmic drugs for major ventricular dysrhythmias